Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.94

€0.94

-4.170%
-0.041
-4.170%
-

-

 
21.04.21 / Frankfurt WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /

Cerenis Therapeutics Holding S.A. Stock

Cerenis Therapeutics Holding S.A. took a tumble today and lost -€0.041 (-4.170%).

Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years

Pros
?
Growth compared to competition
?
Brand
?
Market Position
Cons
?
Conscious of the environment
?
Shareholder structure
?
Worthwhile Investment for the next years
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cerenis Therapeutics Holding S.A. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Cerenis Therapeutics Holding S.A. -4.170% -4.747% -1.975% -9.501% 0.213% -51.740% -88.945%
Genomic Vision S.A. -4.200% 0.177% -18.647% 47.432% -27.139% -71.800% -93.414%
Hybrigenics S.A. -12.890% -20.635% -23.780% 8.696% 23.457% -54.128% -73.348%
Sensorion SA - -4.320% 3.505% 178.967% 50.169% - -

Other discussions about Cerenis Therapeutics Holding S.A. Stock

New thread Forum

News

ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine


ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in